Logo

Phase-1 in Toxicogenomics Service Partnership with NCI

May 05, 2003

NEW YORK, May 5 - Phase-1 Molecular Toxicology said today that it is providing toxicogenomics services for the National Cancer Institute.

 

Specifically, the company said it will analyze the toxicity of cancer treatments in comparison to the mechanism of antitumor action.

 

Phase-1 will receive animal tissues from several contract laboratories performing preclinical safety studies for the NCI and will evaluate the tissues for treatment-related gene expression effects.

 

According to Joseph Tomaszewski, chief of the toxicology and pharmacology branch at NCI, Phase-1 was chosen as NCI's service partner because "they have toxchips for the relevant species in which we perform our toxicity studies."

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.